Featured Research

from universities, journals, and other organizations

Gout drug may reduce risk of death, study shows

Date:
March 25, 2014
Source:
Boston University Medical Center
Summary:
The use of the drug allopurinol was associated with a reduced risk of death in hyperuricemic (gout) patients, a new study has revealed. The study, the first in a general population, has found the overall benefit of allopurinol on survival may outweigh the impact of rare serious adverse effects.

In a recently to be published study in Annals of the Rheumatic Diseases, researchers have found the use of the drug allopurinol was associated with a reduced risk of death in hyperuricemic (gout) patients. The study, the first in a general population, has found the overall benefit of allopurinol on survival may outweigh the impact of rare serious adverse effects.

Researchers from the Section of Rheumatology and Clinical Epidemiology at Boston University School of Medicine (BUSM) contributed to this study.

Gout has been associated with an increased risk of premature death. Allopurinol is the most commonly used urate-lowering medication for this condition but is not without possible side effects. According to the researchers, a rare but potentially fatal adverse reaction affects approximately 1 in 260 allopurinol users and has led to reluctance among some physicians to prescribe this drug despite its potential benefits.

Using The Health Improvement Network database, which contains computerized medical records entered by general practitioners in the United Kingdom, the researchers evaluated the effect of starting allopurinol on the risk of death, among patients who had high uric acid (a blood marker for gout), and those who were diagnosed with gout. They identified 5,927 people who started allopurinol, and used advanced statistical methods to identify the same number of control patients who had similar baseline characteristics, to assure the two groups were comparable. All subjects were followed until they died, or the end of the study period.

"We found that allopurinol initiation was associated with an 11 percent lower risk of all-cause mortality compared with non-initiators in hyperuricemic patients, and a 19 percent lower risk of mortality in gout patients," explained lead author Maureen Dubreuil, MD, an instructor of medicine at BUSM. "These risk reductions were apparent from the first year and throughout the subsequent years of follow-up," she added.

According to Dubreuil this research is important because it shows that treatment with allopurinol may not only treat gout, but it may protect gout patients from premature death.


Story Source:

The above story is based on materials provided by Boston University Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. M. Dubreuil, Y. Zhu, Y. Zhang, J. D. Seeger, N. Lu, Y. H. Rho, H. K. Choi. Allopurinol initiation and all-cause mortality in the general population. Annals of the Rheumatic Diseases, 2014; DOI: 10.1136/annrheumdis-2014-205269

Cite This Page:

Boston University Medical Center. "Gout drug may reduce risk of death, study shows." ScienceDaily. ScienceDaily, 25 March 2014. <www.sciencedaily.com/releases/2014/03/140325100256.htm>.
Boston University Medical Center. (2014, March 25). Gout drug may reduce risk of death, study shows. ScienceDaily. Retrieved August 20, 2014 from www.sciencedaily.com/releases/2014/03/140325100256.htm
Boston University Medical Center. "Gout drug may reduce risk of death, study shows." ScienceDaily. www.sciencedaily.com/releases/2014/03/140325100256.htm (accessed August 20, 2014).

Share This




More Health & Medicine News

Wednesday, August 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola-Hit Sierra Leone's Freetown a City on Edge

Ebola-Hit Sierra Leone's Freetown a City on Edge

AFP (Aug. 19, 2014) Residents of Sierra Leone's capital voice their fears as the Ebola virus sweeps through west Africa. Duration: 00:56 Video provided by AFP
Powered by NewsLook.com
101-Year-Old Working Man Has All The Advice You Need

101-Year-Old Working Man Has All The Advice You Need

Newsy (Aug. 19, 2014) Herman Goldman has worked at the same lighting store for almost 75 years. Find out his secrets to a happy, productive life. Video provided by Newsy
Powered by NewsLook.com
Researcher Testing on-Field Concussion Scanners

Researcher Testing on-Field Concussion Scanners

AP (Aug. 19, 2014) Four Texas high school football programs are trying out an experimental system designed to diagnose concussions on the field. The technology is in response to growing concern over head trauma in America's most watched sport. (Aug. 19) Video provided by AP
Powered by NewsLook.com
American Ebola Patient Apparently Improving, Outbreak Is Not

American Ebola Patient Apparently Improving, Outbreak Is Not

Newsy (Aug. 19, 2014) Nancy Writebol, an American missionary who contracted Ebola, is apparently getting better, according to her husband. The outbreak, however, is not. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins